JPH05380B2 - - Google Patents

Info

Publication number
JPH05380B2
JPH05380B2 JP25386087A JP25386087A JPH05380B2 JP H05380 B2 JPH05380 B2 JP H05380B2 JP 25386087 A JP25386087 A JP 25386087A JP 25386087 A JP25386087 A JP 25386087A JP H05380 B2 JPH05380 B2 JP H05380B2
Authority
JP
Japan
Prior art keywords
substance
methanol
chloroform
culture
nmr spectrum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP25386087A
Other languages
Japanese (ja)
Other versions
JPH0196189A (en
Inventor
Uehito Takeda
Masayuki Takagi
Tadaaki Okada
Shuichi Gomi
Masaji Sezaki
Shinji Myaji
Takashi Shomura
Shinichi Kondo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Seika Kaisha Ltd
Original Assignee
Meiji Seika Kaisha Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha Ltd filed Critical Meiji Seika Kaisha Ltd
Priority to JP25386087A priority Critical patent/JPH0196189A/en
Publication of JPH0196189A publication Critical patent/JPH0196189A/en
Publication of JPH05380B2 publication Critical patent/JPH05380B2/ja
Granted legal-status Critical Current

Links

Description

【発明の詳細な説明】 産業上の利用分野 本発明は新規抗生物質SF2446A2物質、
SF2446A3物質、SF2446B1物質、SF2446B2物質
及びSF2446B3物質に関するものである。 従来の技術及び発明が解決しようとする問題点 従来、数多くの抗生物質が発明、発見され、人
体用医薬品、動物用医薬品、農薬等の分野で実用
化されている。しかしながら、まだ有効な物質が
見出されていないため解決されていない医療或い
は産業の分野が数多く残されている。例えば、一
般細菌及びマイコプラズマにより発症する感染症
は単独感染のほか他の細菌と混合感染する極めて
厄介な病気であり、この分野では強力でしかも広
範囲な抗菌活性と抗マイコプラズマ活性を持つ新
規な抗生物質を提供することが常に要望されてい
る。本発明者らは以上のような点に着目し、新規
な抗生物質を提供するとともに、その製造法を確
立することによつてこれを解決しようとするもの
である。 問題点を解決するための手段 本発明者らは、先にストレプトマイセス属に属
する特定の菌株を培養することにより、各種細菌
及びマイコプラズマに対して強い発育阻止作用を
有する物質が培養液中に生産、蓄積されることを
見出し、その有効物質を採取することに成功し、
SF2446物質と命名した[特願昭61−301156(昭和
61年12月19日出願)]。 本発明者らはこれと同一菌株の培養液中に他の
新規な有効物質を見付けSF2446A2物質、
SF2446A3物質、SF2446B1物質及びSF2446B2物
質と命名した。 またSF2446B1物質又はSF2446B2物質を酸で
処理することにより新規な抗生物質を得、これを
SF2446B3物質と命名した。 これらの本発明物質は下記の理化学的性状を有
する。 [] SF2446A2物質 (1) 色及び形状:赤褐色粉末 (2) 元素分析値:C58.10%,H5.26%,N1.90% (3) 分子式 :C34H35NO15 (4) マススペクトル(FD−MS):m/z697
(M+) (5) 融点 :180−184℃(分解) (6) 紫外部及び可視部吸収スペクトル(第1図) λ max nm(E1% 1cm) [MeOH]:216(648),228sh
(494),251(448),270sh(370),
300sh(211),417(85),472(88) [0.1N HCl−MeOH]:217(610),227sh(475),
250(451),270sh(376),300sh
(211),415(92),470(93) [0.1N NaOH−MeOH]:213(1210),240sh
(535),300sh(212),574(123) (7) 赤外部吸収スペクトル(第6図) (KBr cm-1):3430,2920,2820,1720,
1680,1650,1615,1590,
1560,1510,1460,1410,
1360,1300,1260,1210,
1160,1110,1095,1050,955,
940,890,870,810,800 (8) 1H NMRスペクトル(400MHz,CDCl3
(第11図) δ(ppm):1.22(3H,d),2.32(3H,br s),
3.03(1H,br d),3.14(1H,
dd),3.35(1H,br d),3.42
(3H,s),3.48(3H,s),
3.54(1H,dd),3.57(3H,s),
3.60(3H,s),3.60(1H,dq),
3.87(1H,dd),4.39(1H,br
ddd),4.92(1H,d),4.97
(1H,dd),5.25(1H,dd),
5.96(1H,br s),6.19(1H,
s),6.49(1H,br,s),6.84
(1H,d),8.47(1H,s),
11.85(1H,s),14.26(1H,s (9) 13C NMRスペクトル(100MHz,CDCl3
(第16図) δ(ppm):196.5s,190.2s,188.8s,179.5s,
171.9s,162.5s,160.1s,
147.3s,143.1s,142.7s,
140.5s,133.9s,124.1d,
124.0s,120.0s,118.7s,
116.7d,109.7s,105.3d,
84.6s,83.2d,79.8d,79.1s,
77.5d,70.9d,68.6d,62.8d,
60.8q,58.9q,52.6q,52.2q,
38.1t,23.9q,17.8q (10) 呈色反応:10%硫酸、モリブデン酸試薬に陽
性である。 (11) 溶解性:メタノール、クロロホルム、酢酸
エチル、アセトンに溶け、水に
溶けない。 (12) 薄層クロマトグラフイー:担体シリカゲル
プレート(メルク社製) 展開溶媒系 Rf値 ヘキサン−アセトン(2:1) 0.27 クロロホルム−メタノール(15:1) 0.40 (13) 塩基性、酸性、中性の区別:弱酸性物質 [] SF2446A3物質 (1) 色及び形状:赤褐色粉末 (2) 元素分析値:C59.04%,H4.12%,N2.53% (3) 分子式 :C26H21NO11 (4) マススペクトル(FD−MS):m/z523
(M+) (5) 融点 : >220℃ (6) 紫外部及び可視部吸収スペクトル(第2図) λ max nm(E1% 1cm) [MeOH]:214(587),228sh
(461),258sh(321),272sh
(270),300sh(185),412(48),
516(48) [0.1N HCl−MeOH]:216(512),230sh(400),
255sh(321),275sh(260),
302sh(189),410(63),494(50) [0.1N NaOH−MeOH]:214(1160),232
(465),300sh(193),460sh
(31),581(82) (7) 赤外部吸収スペクトル(第7図) (KBr cm-1):3430,3400,2940,1720,
1680,1650,1625,1590,
1465,1410,1360,1310,
1265,1220,1160,1120,
1090,1050,1000,960,940,
900,875,815,800, (8) 1H NMRスペクトル(400MHz,CDCl3
(第12図) δ(ppm):2.40(3H,br s),3.34(1H,br
d),3.40(3H,s),3.57(1H,
dd),3.85(3H,s),4.68(1H,
br d),4.97(1H,dd),5.24
(1H,br s),5.58(2H,br),
5.95(1H,s),6.54(1H,br
s),8.20(1H,s),12.10
(1H,s),14.32(1H,s) (9) 13C NMRスペクトル(100MHz,CDCl3
(第17図) δ(ppm):196.3s,190.0s,188.7s,179.7s,
172.1s,162.3s,160.1s,
149.0s,143.3s,142.7s,
140.0s,133.9s,124.3d,
123.9s,119.7s,118.8s,
116.2d,109.9s,104.3d,
84.6s,78.8s,62.8d,52.6q,
52.3q,38.0t,23.9q (10) 呈色反応:10%硫酸、モリブデン酸試薬に陽
性である。 (11) 溶解性:メタノール、クロロホルム、酢酸
エチル、アセトンに溶け、水に
溶けない。 (12) 薄層クロマトグラフイー:担体シリカゲル
プレート(メルク社製) 展開溶媒系 Rf値 ヘキサン−アセトン(2:1) 0.39 クロロホルムーメタノール(15:1) 0.42 (13) 塩基性、酸性、中性の区別:弱酸性物質 [] SF2446B1物質 (1) 色及び形状:赤褐色粉末 (2) 元素分析値:C59.72%,H5.35%,N2.21% (3) 分子式 :C34H35NO14 (4) マススペクトル(FD−MS):m/z682
(MH+) (5) 融点 :188−192℃(分解) (6) 紫外部及び可視部吸収スペクトル(第3図) λ max nm(E1% 1cm) [MeOH]:217(624),230sh
(465),252(461),275sh(341),
305sh(170),419(78),471(82) [0.1N HCl−MeOH]:218(587),227sh(461),
252(473),270sh(330),300sh
(191),419(87),469(88) [0.1N NaOH−MeOH]:215(1230),246
(526),300(195),589(129) (7) 赤外部吸収スペクトル(第8図) (KBr cm-1):3450,3370,2940,2830,
1720,1675,1650,1620,
1566,1510,1465,1405,
1365,1310,1260,1240,
1215,1160,1130,1110,
1085,1150,1010,980,950,
920,885,860,815,800 (8) 1H NMRスペクトル(400MHz,CDCl3
(第13図) δ(ppm):1.35(3H,d),2.24(1H,ddd),
2.33(3H,br s),2.63(1H,
br d),2.76(1H,ddd),3.08
(1H,ddd),3.14(1H,ddd),
3.14(1H,dd),3.23(3H,s),
3.34(1H,dq),3.61(3H,s),
3.70(1H,dd),3.75(1H,br
ddd),3.80(3H,s),3.82
(3H,s),4.69(1H,dd),
4.71(1H,s),5.86(1H,s),
6.49(1H,br s),6.84(1H,
d),8.21(1H,s),12.04
(1H,s),14.15(1H,s) (9) 13C NMRスペクトル(100MHz,CDCl3
(第18図) δ(ppm):197.7s,190.3s,188.7s,179.4s,
172.1s,162.4s,160.2s,
147.1s,145.1s,142.4s,
140.9s,133.7s,124.1d,
124.0s,120.9s,118.4s,
116.4d,109.4s,104.2d,
87.1s,82.8d,79.6d,79.2d,
77.9s,75.2d,73.3d,62.5q,
61.2q,52.3q,52.2q,26.7t,
23.8q,18.4t,18.0q (10) 呈色反応:10%硫酸、モリブデン酸試薬に陽
性である。 (11) 溶解性:メタノール、クロロホルム、酢酸
エチル、アセトンに溶け、 水に溶けない。 (12) 薄層クロマトグラフイー:担体シリカゲル
プレート(メルク社製) 展開溶媒系 Rf値 ヘキサン−アセトン(2:1) 0.43 クロロホルム−メタノール(15:1) 0.58 (13) 塩基性、酸性、中性の区別:弱酸性物質 [] SF2446B2物質 (1) 色及び形状:赤褐色粉末 (2) 元素分析値:C59.16%,H5.18%,N2.05% (3) 分子式 :C34H35NO14 (4) マススペクトル(FD−MS):m/z681
(M+) (5) 融点 :177−181℃(分解) (6) 紫外部及び可視部吸収スペクトル(第4図) λ max nm(E1% 1cm) [MeOH]:217(617),228sh
(470),250(455),270sh(355),
300sh(191),418(84),471(88) [0.1N HCl−MeOH]:218(586),227sh(461),
251(464),270sh(370),305sh
(181),416(85),470(90) [0.1N NaOH−MeOH]:214(1180),246
(501),300(195),585(128) (7) 赤外部吸収スペクトル(第9図) (KBr cm-1):3430,2930,2830,1720,
1680,1650,1620,1590,
1560,1515,1465,1405,
1365,1310,1265,1240,
1215,1165,1100,1040,
1020,995,950,920,885,
810,800 (8) 1H NMRスペクトル(400MHz,CDCl3
(第14図) δ(ppm):1.27(3H,d),2.26(1H,ddd),
2.37(3H,br s),2.65(1H,
d),2.77(1H,ddd),3.08
(1H,ddd),3.10(1H,dd),
3.12(1H,ddd),3.25(3H,
s),3.50(3H,dq),3.55(3H,
s),3.56(3H,s),3.68(1H,
dd),3.80(3H,s),4.02(1H,
ddd),4.86(1H,s),5.19
(1H,dd),6.19(1H,s),
6.40(1H,d),6.50(1H,br
s),8.34(1H,s),12.06
(1H,s),14.19(1H,s) (9) 13C NMRスペクトル(100MHz,CDCl3
(第19図) δ(ppm):198.1s,190.2s,188.7s,179.6s,
172.1s,162.5s,160.2s,
147.3s,145.0s,142.4s,
141.2s,133.7s,124.2d,
124.1s,120.9s,118.4s,
116.8d,109.5s,105.5d,
87.2s,83.0d,79.8d,78.1s,
77.5d,70.8d,68.7d,60.7q,
58.9q,52.3q,52.2q,26.7t,
23.9q,18.5t,17.7q, (10) 呈色反応:10%硫酸、モリブデン酸試薬に陽
性である。 (11) 溶解性:メタノール、クロロホルム、酢酸
エチル、アセトンに溶け、水に
溶けない。 (12) 薄層クロマトグラフイー:担体シリカゲル
プレート(メルク社製) 展開溶媒系 Rf値 ヘキサン−アセトン(2:1) 0.35 クロロホルム−メタノール(15:1) 0.45 (13) 塩基性、酸性、中性の区別:弱酸性物質 [] SF2446B3物質 (1) 色及び形状:赤褐色粉末 (2) 分子式 :C26H21NO10 (3) マススペクトル(FD−MS):m/z507
(M+) (4) 融点 :187−192℃ (5) 紫外部及び可視部吸収スペクトル(第5図) λ max nm(E1% 1cm) [MeOH]:217(680),227sh
(517),251(464),275sh(345),
300sh(231),409(87),489(73) [0.1N HCl−MeOH]:218(645),227sh(501),
251(473),272sh(361),300sh
(241),410(91),493(75) [0.1N NaOH−MeOH]:215(1220),240sh
(511), 285sh(245),460(47),587
(128) (6) 赤外部吸収スペクトル(第10図) (KBr cm-1):3440,3360,2950,1720,
1685,1650,1625,1590,
1465,1405,1360,1310,
1260,1220,1165,1105,
1080,1050,1005,955,915,
890,815,800 (7) 1H NMRスペクトル(400MHz,CDCl3
(第15図) δ(ppm):2.27(1H,ddd),2.38(3H,br s),
2.76(1H,ddd),3.08(1H,
ddd),3.15(1H,ddd),3.23
(3H,s),3.84(3H,s),
4.70(1H,s),5.43(2H,br),
5.94(1H,s),6.51(1H,br
s),8.22(1H,s),12.06
(1H,s),14.25(1H,s) (8) 13C NMRスペクトル(100MHz,CDCl3
(第20図) δ(ppm):197.9s,190.3s,188.8s,179.8s,
172.2s,162.4s,160.3s,
148.9s,145.1s,142.4s,
140.9s,133.7s,124.2d,
124.1s,120.9s,118.6s,
116.4d,109.5s,104.5d,
87.1s,78.0s,52.3×2q,26.8t,
23.9q,18.5t (9) 呈色反応:10%硫酸、モリブデン酸試薬に陽
性である。 (10) 溶解性:メタノール、クロロホルム、酢酸エ
チル、アセトンに溶け、水に溶
けない。 (11) 薄層クロマトグラフイー:担体シリカゲル
プレート(メルク社製) 展開溶媒系 Rf値 ヘキサン−アセトン(2:1) 0.46 クロロホルムーメタノール(15:1) 0.50 (12) 塩基性、酸性、中性の区別:弱酸性物質 本願発明物質は下記の化学構造式で示される。 【表】 本発明に使用される新規抗生物質の生産菌の一
例としては、兵庫県の土壌から新たに分離された
SF2446株がある。 SF2446株の菌学的性状は下記の通りである。 形態 基生菌糸は長く伸張し、よく分岐し、通常の条
件下では分断しない。気菌糸の着生は貧弱である
が、オートミール寒天、スターチ寒天、グリセロ
ール・アスパラギン寒天、シユクロース・硝酸塩
寒天等で着生し、胞子形成も認められる。気菌糸
の分岐は単純分岐で車軸分岐は見られない。気菌
糸先端の胞子連鎖は波状、ループ状、フツク状、
あるいは不完全は螺旋状となる。電子顕微鏡によ
る観察では、胞子は円筒型ないし楕円型で、0.5
〜1.1×0.6〜1.3μmの大きさを有し、表面はしわ
状(rugose)ないし刺状(spiny)である。胞子
は通常50個以上連鎖する。胞子嚢、運動性胞子、
菌核等は観察されない。 各種培地上の生育状態 SF2446株の各種培地上の生育状態は第1表に
示す通りである。色の記載について[ ]内に示
す標準はコンテイーナー・コーポレーシヨン・オ
ブ・アメリカ(Container Corporation of
America)社製の「カラー・ハーモニー・マニ
アル(Color Harmony Maumal)」に記載され
ているものを用いた。観察は28℃で14〜21日間培
養後に行なつた。 【表】 生理的性質 (1) 生育温度範囲:イースト麦芽寒天において20
〜37℃の温度範囲で生育し、26〜30℃で良好に
生育する。 (2) ゼラチンの液化:陰性 (3) スターチの加水分解:陰性 (4) 硝酸塩の還元:陰性 (5) 脱脂乳のペプトン化:陰性 脱脂乳の凝固:陰性 (6) 耐塩性:4%の食塩含有培地では生育する
が、5%以上では生育しない。 (7) メラニン様色素の生成:陰性 炭素源の利用性(ISP No.9培地使用) (1) 利用する :D−グルコース、グリセロール (2) 利用しない:D−キシロース、L−アラビノ
ース、D−マンニトール、i−イノシトール、
ラフイノース、シユクロース (3) 利用が疑わしい:D−フラクトース、L−ラ
ムノース 細胞壁組成 ベツカー(Becker)らの方法(Appl.
Microbiol.13,236,1965)により分析した結果、
細胞壁組成成分中のジアミノピメリン酸はLL型
であつた。 以上の性状より、SF2446株は放線菌の中でス
トレプトマイセス属に属すると考えるのが妥当で
ある。従つて、本発明者らはSF2446株をストレ
プトマイセス・エスピー・SF2446
(Streptomyces sp.SF2446)と称することにし
た。 SF2446株は工業技術院微生物工業技術研究所
に微工研菌寄第8980号(FERM P−8980)とし
て受託されている。 SF2446株は他の放線菌の場合に見られるよう
に、その性状が変化しやすい。例えば、SF2446
株の、またはこの株に由来する突然変異株(自然
発生または誘発性)、形質接合体または遺伝子組
み換え体であつても、本願にかかわる抗生物質を
生産するものは全て本発明に使用できる。本発明
の方法では、前記の菌を通常の微生物が利用しう
る栄養物を含有する培地で培養する。栄養源とし
ては、グルコース、水飴、デキストリン、シユク
ロース、澱粉、糖蜜、動、植物油等を使用出来
る。また窒素源として、大豆粉、小麦胚芽、コー
ンステイプリカー、綿実粕、肉エキス、ペプト
ン、酵母エキス、硫酸アンモニウム、硝酸ソー
ダ、尿素等を使用出来る。その他、必要に応じて
ナトリウム、カリウム、マグネシウム、コバル
ト、塩素、燐酸、硫酸、及びその他のイオンを生
じることができる無機塩類を添加することは有効
である。また菌の発育を助け、本願にかかわる抗
生物質の生産を促進するような有機及び無機質を
適当に添加することができる。 培養法としては、好気的条件での培養法、特に
深部培養法が最も適している。培養に適当な温度
は20〜37℃であるが、多くの場合26〜30℃付近で
培養する。本願にかかわる抗生物質の生産は培地
や培養条件により異なるが、振盪培養、タンク培
養とも通常1〜8日の間でその蓄積が最高に達す
る。培養液中の本願にかかわる抗生物質の蓄積量
が最高になつた時に培養を停止し、培養液から目
的物質を単離精製する。 このようにして生産される本願抗生物質は前記
の理化学的性状を有するので、その性状に従つて
培養液から抽出、精製することが可能であるが、
特に以下に述べる方法により効率的に抽出、精製
することが出来る。すなわち、有効成分を含有す
る培養液に酢酸エチル等の水と自由に混和しない
有機溶媒を加えて攪拌、抽出する。一方、固形物
はアセトン等の水と自由に混和する有機溶媒と水
を加えて攪拌し、固形分から有効成分を抽出し、
有機溶媒を留去した後、酢酸エチル等の水と自由
に混和しない有機溶媒を用いて有効成分を抽出す
る。このようにして得られた油状物質をシリカゲ
ル、アルミナ、ゲル濾過剤等の担体を適宜組み合
わせたクロマトグラフイーにより本願抗生物質を
単離する。 発明の効果 本発明にかかわる抗生物質は主としてグラム陽
性の一般細菌及びマイコプラズマに対して強い抗
菌作用を有する。一般細菌では日本化学療法学会
法の寒天平板希釈法(Chemotherapy29,76−
79,1981)に従い、マイコプラズマではPPLOブ
ロス培地を使用した液体希釈法(Chemotherapy
23,2569−2576,1975)に準じて測定した抗生物
質SF2446物質、SF2446A2物質、SF2446A3物
質、SF2446B1物質、SF2446B2物質及び
SF2446B3物質に各種微生物に対する最小発育阻
止濃度(MIC)は第2表に示す通りである。 【表】 【表】 実施例 1 種培地として、スターチ2.0%、グルコース1.0
%、小麦胚芽0.6%、ポリペプトン0.5%、酵母エ
キス0.3%、大豆粉0.2%、炭酸カルシウム0.1%を
含む培地を用いた。また生産培地として、グルコ
ース3.0%、小麦胚芽1.5%、大豆粉0.5%、コーン
ステイープリカー1.0%、炭酸カルシウム0.1%、
塩化コバルト0.001%を含む培地を用いた。なお、
殺菌前PHはすべてPH7.0に調整した。 前記種培地20mlを分注した100ml容三角フラス
コを120℃で30分間殺菌し、これにストレプトマ
イセス・エスピー・SF2446(FERM P−8980)
の斜面培養の1−2白金耳を接種し、28℃で3日
間振とう培養し第1種培養とした。次いで種培地
80mlを分注した500ml容三角フラスコを120℃で30
分間殺菌し、前記第1種培養4mlを接種後、28℃
で2日間振とう培養して、これを第2種培養とし
た。更に種培地1Lを分注した5L容三角フラスコ
を120℃で30分間殺菌し、第2種培養50mlを接種
後、28℃で1日間振とう培養して、これを第3種
培養とした。更に予め120℃で30分間殺菌した種
培地25Lを分注した50L容ジヤーフアメンターに、
第3種培養1Lを接種し、28℃で1日間通気攪拌
培養し、これを第4種培養とした。 予め120℃で30分間殺菌した200Lの生産培地を
含む300L容ジヤーフアメンターに、前記の第4
種培養25Lを接種し、28℃で5日間通気(20L/
分)、攪拌(初期100rpm,48時間以降130rpm)
培養した。培養終了後、濾過助剤として珪藻土を
加え濾過した。 濾過後に得られた菌体を含む固形分に70%アセ
トン水158Lを加えて1時間攪拌し、再び濾過し
て有効成分を含む菌体抽出液158Lを得た。更に
菌体抽出液を減圧濃縮してアセトンを留去した水
層54LをPH7に調整し、酢酸エチル54Lを加えて
1時間攪拌して有効成分を抽出した。この操作を
2回繰り返し、得られた酢酸エチル抽出液に無水
硫酸ナトリウムを加えて乾燥後、約2Lまで減圧
濃縮した。濃縮液は5℃で1週間放置後、析出し
た結晶を濾別し、冷メタノール次いでヘキサンで
洗浄して乾燥すると、8.59gのSF2446物質が得ら
れた。この濾液と洗浄液を合わせて減圧濃縮する
と、赤褐色の油状物質が得られた。 この油状物質をクロロホルムで予め充填したシ
リカゲルカラム2.4L(ワコーゲルC−300、和光純
薬社製)の上部にのせ、クロロホルム5Lで洗浄
後、クロロホルム−メタノール(10:1)で展開
して活性画分を集め減圧濃縮すると、油状物質が
得られた。この操作を2回繰り返し、得られた油
状物質を同様のシリカゲルカラム2.4Lの上部にの
せ、クロロホルム1Lで洗浄後、クロロホルム−
メタノール(50:1)、200mlフラクシヨンカツト
で展開すると、フラクヨン3〜6(Fr.)に
SF2446B1物質を主に含む活性区が、フラクシヨ
ン7〜14(Fr.)にSF2446物質及びSF2446A3物
質を主に含む活性区が、フラクシヨン15〜18(Fr.
)にSF2446B2物質を主に含む活性区が、フラ
クシヨン19〜28(Fr.)及びフラクシヨン29〜40
(Fr.)にSF2446A2物質を主に含む活性区が得
られた。Fr.を減圧濃縮乾固すると、650mgの油
状物質が得られた。この油状物質を予めヘキサン
−アセトン(2:1)で充填したシリカゲルカラ
ム120mlの上部にのせ、同様の溶媒系で展開する
と、SF2446B1物質を主に含む粗物質が得られ
た。この粗物質を更に分取用シリカゲルTLC(展
開系:ヘキサン−アセトン1:1)で精製する
と、80.5mgのSF2446B1物質が得られた。Fr.を
減圧濃縮乾固すると、10.51gの粗物質が得られ
た。この粗物質をクロロホルム−メタノール
(1:1)混液を用いて再結晶を行うと、1.82gの
SF2446物質が得られた。濾液を減圧濃縮し、得
られた粗物質はクロロホルム−メタノール(1:
1)を展開溶媒とするセフアデツクスLH−20
(750ml,Pharmacia社製)のカラムクロマトグ
ラフイーを行い、活性画分を減圧濃縮乾固した。
更にこの操作を2回繰り返すと、570mgのSF2446
物質及び303mgの主にSF2446A3物質を含む粗物
質が得られた。この粗物質をシリカゲルカラム
(30g、展開系:クロロホルム−メタノール30:
1)次いで分取用シリカゲルカラムTLC(展開
系:クロロホルム−メタノール15:1)で精製す
ると、23.7mgのSF2446A3物質が得られた。Fr.
を減圧濃縮乾固すると、772mgの粗物質が得られ
た。この粗物質はクロロホルム−メタノール
(30:1)を展開溶媒とするシリカゲル(80g)
カラムクロマトグラフイーを行い、得られた活性
画分を減圧濃縮乾固すると、123mgの粗物質が得
られた。更にこの粗物質を分取用シリカゲル
TLC(展開系:トルエン−酢酸エチル1:2、次
いでクロロホルム−メタノール15:1)で精製す
ると、78.8mgのSF2446B2物質が得られた。Fr.
を減圧濃縮乾固すると、5.07gのSF2446A2物質が
得られた。同様にFr.を減圧濃縮乾固すると、
5.72gの粗物質が得られた。この粗物質はシリカ
ゲル(300g、展開系:クロロホルム−メタノー
ル50:1)カラムクロマトグラフイー、次いでシ
リカゲル(300g、展開系:ヘキサン−アセトン
2:1)カラムクロマトグラフイー、更にセフア
デツクスLH−20(展開系:クロロホルム−メタ
ノール1:1)カラムクロマトグラフイーを行
い、1.13gのSF2446A2物質が得られた。 実施例 2 SF2446B1物質(15.2mg)のメタノール溶液
(2.2ml)に濃塩酸(0.2ml)を加えて、40℃で1
時間放置した。その後、減圧下に溶媒を留去し、
残査を分取用シリカゲルTLC(展開系:クロロホ
ルム−メタノール15:1)で精製すると、5.4mg
のSF2446B3物質が得られた。
[Detailed description of the invention] Industrial application field The present invention provides a novel antibiotic SF2446A2 substance,
This relates to SF2446A3 substance, SF2446B1 substance, SF2446B2 substance and SF2446B3 substance. Background Art and Problems to be Solved by the Invention Conventionally, many antibiotics have been invented and discovered, and have been put to practical use in the fields of human medicine, veterinary medicine, agricultural chemicals, and the like. However, there are still many medical and industrial fields that remain unsolved because no effective substances have been found. For example, infectious diseases caused by common bacteria and mycoplasma are extremely troublesome diseases that can occur alone or in combination with other bacteria. It is always requested to provide The present inventors have focused on the above-mentioned points, and aim to solve the problems by providing a new antibiotic and establishing a method for producing the same. Means for Solving the Problems The present inventors have discovered that by first culturing a specific strain belonging to the genus Streptomyces, a substance that has a strong growth-inhibiting effect on various bacteria and mycoplasma is contained in the culture solution. discovered that it is produced and accumulated, and succeeded in collecting its effective substance,
The substance was named SF2446 [Patent application 1986-301156 (Showa
Filed on December 19, 1961)]. The present inventors discovered other new effective substances in the culture solution of the same strain, SF2446A2 substance,
They were named SF2446A3 substance, SF2446B1 substance and SF2446B2 substance. In addition, a new antibiotic can be obtained by treating SF2446B1 substance or SF2446B2 substance with acid.
The substance was named SF2446B3. These substances of the present invention have the following physical and chemical properties. [] SF2446A2 substance (1) Color and shape: Reddish brown powder (2) Elemental analysis: C58.10%, H5.26%, N1.90% (3) Molecular formula: C 34 H 35 NO 15 (4) Mass spectrum (FD-MS): m/z697
(M + ) (5) Melting point: 180-184℃ (decomposition) (6) Ultraviolet and visible absorption spectra (Figure 1) λ max nm (E1% 1cm) [MeOH]: 216 (648), 228sh
(494), 251 (448), 270sh (370),
300sh (211), 417 (85), 472 (88) [0.1N HCl-MeOH]: 217 (610), 227sh (475),
250 (451), 270sh (376), 300sh
(211), 415 (92), 470 (93) [0.1N NaOH−MeOH]: 213 (1210), 240sh
(535), 300sh (212), 574 (123) (7) Infrared absorption spectrum (Figure 6) (KBr cm -1 ): 3430, 2920, 2820, 1720,
1680, 1650, 1615, 1590,
1560, 1510, 1460, 1410,
1360, 1300, 1260, 1210,
1160, 1110, 1095, 1050, 955,
940, 890, 870, 810, 800 (8) 1 H NMR spectrum (400MHz, CDCl 3 )
(Figure 11) δ (ppm): 1.22 (3H, d), 2.32 (3H, br s),
3.03 (1H, br d), 3.14 (1H,
dd), 3.35 (1H, br d), 3.42
(3H, s), 3.48 (3H, s),
3.54 (1H, dd), 3.57 (3H, s),
3.60 (3H, s), 3.60 (1H, dq),
3.87 (1H, dd), 4.39 (1H, br
ddd), 4.92 (1H, d), 4.97
(1H, dd), 5.25 (1H, dd),
5.96 (1H, br s), 6.19 (1H,
s), 6.49 (1H, br, s), 6.84
(1H, d), 8.47 (1H, s),
11.85 (1H, s), 14.26 (1H, s (9) 13 C NMR spectrum (100MHz, CDCl 3 )
(Figure 16) δ (ppm): 196.5s, 190.2s, 188.8s, 179.5s,
171.9s, 162.5s, 160.1s,
147.3s, 143.1s, 142.7s,
140.5s, 133.9s, 124.1d,
124.0s, 120.0s, 118.7s,
116.7d, 109.7s, 105.3d,
84.6s, 83.2d, 79.8d, 79.1s,
77.5d, 70.9d, 68.6d, 62.8d,
60.8q, 58.9q, 52.6q, 52.2q,
38.1t, 23.9q, 17.8q (10) Color reaction: Positive for 10% sulfuric acid and molybdate reagents. (11) Solubility: Soluble in methanol, chloroform, ethyl acetate, acetone, insoluble in water. (12) Thin layer chromatography: Support silica gel plate (manufactured by Merck) Developing solvent system Rf value Hexane-acetone (2:1) 0.27 Chloroform-methanol (15:1) 0.40 (13) Basic, acidic, neutral Distinction: Weakly acidic substance [] SF2446A3 substance (1) Color and shape: Reddish brown powder (2) Elemental analysis: C59.04%, H4.12%, N2.53% (3) Molecular formula: C 26 H 21 NO 11 (4) Mass spectrum (FD-MS): m/z523
(M + ) (5) Melting point: >220℃ (6) Ultraviolet and visible absorption spectra (Figure 2) λ max nm (E1% 1cm) [MeOH]: 214 (587), 228sh
(461), 258sh (321), 272sh
(270), 300sh (185), 412 (48),
516 (48) [0.1N HCl-MeOH]: 216 (512), 230sh (400),
255sh (321), 275sh (260),
302sh (189), 410 (63), 494 (50) [0.1N NaOH-MeOH]: 214 (1160), 232
(465), 300sh (193), 460sh
(31), 581(82) (7) Infrared absorption spectrum (Figure 7) (KBr cm -1 ): 3430, 3400, 2940, 1720,
1680, 1650, 1625, 1590,
1465, 1410, 1360, 1310,
1265, 1220, 1160, 1120,
1090, 1050, 1000, 960, 940,
900, 875, 815, 800, (8) 1 H NMR spectrum (400MHz, CDCl 3 )
(Fig. 12) δ (ppm): 2.40 (3H, br s), 3.34 (1H, br s)
d), 3.40 (3H, s), 3.57 (1H,
dd), 3.85 (3H, s), 4.68 (1H,
br d), 4.97 (1H, dd), 5.24
(1H, br s), 5.58 (2H, br),
5.95 (1H, s), 6.54 (1H, br
s), 8.20 (1H, s), 12.10
(1H, s), 14.32 (1H, s) (9) 13C NMR spectrum (100MHz, CDCl 3 )
(Figure 17) δ (ppm): 196.3s, 190.0s, 188.7s, 179.7s,
172.1s, 162.3s, 160.1s,
149.0s, 143.3s, 142.7s,
140.0s, 133.9s, 124.3d,
123.9s, 119.7s, 118.8s,
116.2d, 109.9s, 104.3d,
84.6s, 78.8s, 62.8d, 52.6q,
52.3q, 38.0t, 23.9q (10) Color reaction: Positive for 10% sulfuric acid and molybdate reagents. (11) Solubility: Soluble in methanol, chloroform, ethyl acetate, acetone, insoluble in water. (12) Thin layer chromatography: Support silica gel plate (manufactured by Merck) Developing solvent system Rf value Hexane-acetone (2:1) 0.39 Chloroform-methanol (15:1) 0.42 (13) Basic, acidic, neutral Distinction: Weakly acidic substance [] SF2446B1 substance (1) Color and shape: Reddish brown powder (2) Elemental analysis: C59.72%, H5.35%, N2.21% (3) Molecular formula: C 34 H 35 NO 14 (4) Mass spectrum (FD-MS): m/z682
(MH + ) (5) Melting point: 188-192℃ (decomposed) (6) Ultraviolet and visible absorption spectra (Figure 3) λ max nm (E1% 1cm) [MeOH]: 217 (624), 230sh
(465), 252 (461), 275sh (341),
305sh (170), 419 (78), 471 (82) [0.1N HCl-MeOH]: 218 (587), 227sh (461),
252 (473), 270sh (330), 300sh
(191), 419 (87), 469 (88) [0.1N NaOH−MeOH]: 215 (1230), 246
(526), 300 (195), 589 (129) (7) Infrared absorption spectrum (Figure 8) (KBr cm -1 ): 3450, 3370, 2940, 2830,
1720, 1675, 1650, 1620,
1566, 1510, 1465, 1405,
1365, 1310, 1260, 1240,
1215, 1160, 1130, 1110,
1085, 1150, 1010, 980, 950,
920, 885, 860, 815, 800 (8) 1 H NMR spectrum (400MHz, CDCl 3 )
(Figure 13) δ (ppm): 1.35 (3H, d), 2.24 (1H, ddd),
2.33 (3H, br s), 2.63 (1H,
br d), 2.76 (1H, ddd), 3.08
(1H, ddd), 3.14 (1H, ddd),
3.14 (1H, dd), 3.23 (3H, s),
3.34 (1H, dq), 3.61 (3H, s),
3.70 (1H, dd), 3.75 (1H, br
ddd), 3.80 (3H, s), 3.82
(3H, s), 4.69 (1H, dd),
4.71 (1H, s), 5.86 (1H, s),
6.49 (1H, br s), 6.84 (1H,
d), 8.21 (1H, s), 12.04
(1H, s), 14.15 (1H, s) (9) 13C NMR spectrum (100MHz, CDCl 3 )
(Figure 18) δ (ppm): 197.7s, 190.3s, 188.7s, 179.4s,
172.1s, 162.4s, 160.2s,
147.1s, 145.1s, 142.4s,
140.9s, 133.7s, 124.1d,
124.0s, 120.9s, 118.4s,
116.4d, 109.4s, 104.2d,
87.1s, 82.8d, 79.6d, 79.2d,
77.9s, 75.2d, 73.3d, 62.5q,
61.2q, 52.3q, 52.2q, 26.7t,
23.8q, 18.4t, 18.0q (10) Color reaction: Positive for 10% sulfuric acid and molybdate reagents. (11) Solubility: Soluble in methanol, chloroform, ethyl acetate, acetone, insoluble in water. (12) Thin layer chromatography: Support silica gel plate (manufactured by Merck) Developing solvent system Rf value Hexane-acetone (2:1) 0.43 Chloroform-methanol (15:1) 0.58 (13) Basic, acidic, neutral Distinction: Weakly acidic substance [] SF2446B2 substance (1) Color and shape: Reddish brown powder (2) Elemental analysis: C59.16%, H5.18%, N2.05% (3) Molecular formula: C 34 H 35 NO 14 (4) Mass spectrum (FD-MS): m/z681
(M + ) (5) Melting point: 177-181℃ (decomposed) (6) Ultraviolet and visible absorption spectra (Figure 4) λ max nm (E1% 1cm) [MeOH]: 217 (617), 228sh
(470), 250 (455), 270sh (355),
300sh (191), 418 (84), 471 (88) [0.1N HCl-MeOH]: 218 (586), 227sh (461),
251 (464), 270sh (370), 305sh
(181), 416 (85), 470 (90) [0.1N NaOH−MeOH]: 214 (1180), 246
(501), 300 (195), 585 (128) (7) Infrared absorption spectrum (Figure 9) (KBr cm -1 ): 3430, 2930, 2830, 1720,
1680, 1650, 1620, 1590,
1560, 1515, 1465, 1405,
1365, 1310, 1265, 1240,
1215, 1165, 1100, 1040,
1020, 995, 950, 920, 885,
810, 800 (8) 1 H NMR spectrum (400MHz, CDCl 3 )
(Figure 14) δ (ppm): 1.27 (3H, d), 2.26 (1H, ddd),
2.37 (3H, br s), 2.65 (1H,
d), 2.77 (1H, ddd), 3.08
(1H, ddd), 3.10 (1H, dd),
3.12 (1H, ddd), 3.25 (3H,
s), 3.50 (3H, dq), 3.55 (3H,
s), 3.56 (3H, s), 3.68 (1H,
dd), 3.80 (3H, s), 4.02 (1H,
ddd), 4.86 (1H, s), 5.19
(1H, dd), 6.19 (1H, s),
6.40 (1H, d), 6.50 (1H, br
s), 8.34 (1H, s), 12.06
(1H, s), 14.19 (1H, s) (9) 13C NMR spectrum (100MHz, CDCl 3 )
(Figure 19) δ (ppm): 198.1s, 190.2s, 188.7s, 179.6s,
172.1s, 162.5s, 160.2s,
147.3s, 145.0s, 142.4s,
141.2s, 133.7s, 124.2d,
124.1s, 120.9s, 118.4s,
116.8d, 109.5s, 105.5d,
87.2s, 83.0d, 79.8d, 78.1s,
77.5d, 70.8d, 68.7d, 60.7q,
58.9q, 52.3q, 52.2q, 26.7t,
23.9q, 18.5t, 17.7q, (10) Color reaction: Positive for 10% sulfuric acid and molybdate reagent. (11) Solubility: Soluble in methanol, chloroform, ethyl acetate, acetone, insoluble in water. (12) Thin layer chromatography: Support silica gel plate (manufactured by Merck) Developing solvent system Rf value Hexane-acetone (2:1) 0.35 Chloroform-methanol (15:1) 0.45 (13) Basic, acidic, neutral Distinction: Weakly acidic substance [] SF2446B3 substance (1) Color and shape: Reddish brown powder (2) Molecular formula: C 26 H 21 NO 10 (3) Mass spectrum (FD-MS): m/z507
(M + ) (4) Melting point: 187-192℃ (5) Ultraviolet and visible absorption spectra (Figure 5) λ max nm (E1% 1cm) [MeOH]: 217 (680), 227sh
(517), 251 (464), 275sh (345),
300sh (231), 409 (87), 489 (73) [0.1N HCl-MeOH]: 218 (645), 227sh (501),
251 (473), 272sh (361), 300sh
(241), 410 (91), 493 (75) [0.1N NaOH−MeOH]: 215 (1220), 240sh
(511), 285sh (245), 460 (47), 587
(128) (6) Infrared absorption spectrum (Figure 10) (KBr cm -1 ): 3440, 3360, 2950, 1720,
1685, 1650, 1625, 1590,
1465, 1405, 1360, 1310,
1260, 1220, 1165, 1105,
1080, 1050, 1005, 955, 915,
890, 815, 800 (7) 1 H NMR spectrum (400MHz, CDCl 3 )
(Fig. 15) δ (ppm): 2.27 (1H, ddd), 2.38 (3H, br s),
2.76 (1H, ddd), 3.08 (1H,
ddd), 3.15 (1H, ddd), 3.23
(3H, s), 3.84 (3H, s),
4.70 (1H, s), 5.43 (2H, br),
5.94 (1H, s), 6.51 (1H, br
s), 8.22 (1H, s), 12.06
(1H, s), 14.25 (1H, s) (8) 13C NMR spectrum (100MHz, CDCl 3 )
(Figure 20) δ (ppm): 197.9s, 190.3s, 188.8s, 179.8s,
172.2s, 162.4s, 160.3s,
148.9s, 145.1s, 142.4s,
140.9s, 133.7s, 124.2d,
124.1s, 120.9s, 118.6s,
116.4d, 109.5s, 104.5d,
87.1s, 78.0s, 52.3×2q, 26.8t,
23.9q, 18.5t (9) Color reaction: Positive for 10% sulfuric acid and molybdate reagents. (10) Solubility: Soluble in methanol, chloroform, ethyl acetate, acetone, insoluble in water. (11) Thin layer chromatography: Support silica gel plate (manufactured by Merck) Developing solvent system Rf value Hexane-acetone (2:1) 0.46 Chloroform-methanol (15:1) 0.50 (12) Basic, acidic, neutral Distinction: Weakly acidic substances The substance of the present invention is represented by the chemical structural formula below. [Table] As an example of the bacteria producing the new antibiotic used in the present invention,
There are SF2446 stocks. The mycological properties of SF2446 strain are as follows. Morphology The basal hyphae are elongated, well branched, and do not divide under normal conditions. Although the aerial mycelium is poorly attached, it grows on oatmeal agar, starch agar, glycerol/asparagine agar, sucrose/nitrate agar, etc., and spore formation is also observed. The branching of aerial hyphae is simple, and no axle branching is observed. The spore chain at the tip of the aerial hyphae is wavy, loop-shaped, hook-shaped,
Or the imperfection becomes a spiral. When observed using an electron microscope, the spores are cylindrical or oval in shape, with a diameter of 0.5
It has a size of ~1.1 x 0.6 to 1.3 μm, and the surface is rugose or spiny. Spores usually form chains of 50 or more. sporangia, motile spores,
No sclerotia etc. are observed. Growth status on various media The growth status of SF2446 strain on various media is as shown in Table 1. Regarding color descriptions, the standards shown in parentheses are those of Container Corporation of America.
The one described in "Color Harmony Maumal" manufactured by America) was used. Observations were made after culturing at 28°C for 14 to 21 days. [Table] Physiological properties (1) Growth temperature range: 20% on yeast malt agar
It grows in a temperature range of ~37°C and grows well at 26-30°C. (2) Liquefaction of gelatin: Negative (3) Hydrolysis of starch: Negative (4) Reduction of nitrate: Negative (5) Peptonization of skim milk: Negative Coagulation of skim milk: Negative (6) Salt tolerance: 4% It grows in a medium containing salt, but does not grow in a medium containing 5% or more salt. (7) Production of melanin-like pigment: Negative Carbon source utilization (ISP No.9 medium used) (1) Used: D-glucose, glycerol (2) Not used: D-xylose, L-arabinose, D- mannitol, i-inositol,
Raffinose, sucrose (3) Use is questionable: D-fructose, L-rhamnose Cell wall composition Method of Becker et al. (Appl.
Microbiol. 13 , 236, 1965).
Diaminopimelic acid in the cell wall composition was of the LL type. Based on the above characteristics, it is reasonable to consider that strain SF2446 belongs to the genus Streptomyces among actinomycetes. Therefore, the present inventors used the SF2446 strain as Streptomyces sp. SF2446.
(Streptomyces sp. SF2446). Strain SF2446 has been entrusted to the Institute of Microbial Technology, Agency of Industrial Science and Technology as FERM P-8980. The SF2446 strain is susceptible to changes in its properties, as seen in the case of other actinomycetes. For example, SF2446
Any strain or mutant strain (naturally occurring or induced) derived from this strain, phenozygote or genetically modified strain that produces the antibiotic according to the present application can be used in the present invention. In the method of the present invention, the above bacteria are cultured in a medium containing nutrients that can be used by common microorganisms. As a nutrient source, glucose, starch syrup, dextrin, sucrose, starch, molasses, animal or vegetable oil, etc. can be used. Further, as a nitrogen source, soybean flour, wheat germ, corn staple liquor, cottonseed meal, meat extract, peptone, yeast extract, ammonium sulfate, sodium nitrate, urea, etc. can be used. In addition, it is effective to add, if necessary, inorganic salts capable of producing sodium, potassium, magnesium, cobalt, chlorine, phosphoric acid, sulfuric acid, and other ions. In addition, organic and inorganic substances that aid the growth of bacteria and promote the production of the antibiotics related to the present application can be appropriately added. The most suitable culture method is a culture method under aerobic conditions, especially a deep culture method. The appropriate temperature for culturing is 20 to 37°C, but in most cases it is cultured at around 26 to 30°C. Although the production of the antibiotic related to the present application differs depending on the culture medium and culture conditions, the accumulation usually reaches its maximum within 1 to 8 days in both shaking culture and tank culture. When the accumulated amount of the antibiotic according to the present invention in the culture solution reaches its maximum, the culture is stopped, and the target substance is isolated and purified from the culture solution. Since the antibiotic of the present application produced in this way has the above-mentioned physicochemical properties, it is possible to extract and purify it from the culture solution according to the properties.
In particular, it can be efficiently extracted and purified by the method described below. That is, an organic solvent that is not freely miscible with water, such as ethyl acetate, is added to the culture solution containing the active ingredient, followed by stirring and extraction. On the other hand, the solids are mixed with water and an organic solvent such as acetone that is freely miscible with water, and the active ingredients are extracted from the solids.
After distilling off the organic solvent, the active ingredient is extracted using an organic solvent that is not freely miscible with water, such as ethyl acetate. The antibiotic of the present invention is isolated by chromatography of the thus obtained oily substance using a suitable combination of carriers such as silica gel, alumina, and gel filtration agents. Effects of the Invention The antibiotic according to the present invention has a strong antibacterial effect mainly against general Gram-positive bacteria and mycoplasma. For general bacteria, the agar plate dilution method of the Japanese Society of Chemotherapy (Chemotherapy 29 , 76-
79, 1981), mycoplasmas were treated using the liquid dilution method (Chemotherapy) using PPLO broth medium.
Antibiotic SF2446 substance, SF2446A2 substance, SF2446A3 substance, SF2446B1 substance, SF2446B2 substance and
The minimum inhibitory concentration (MIC) of SF2446B3 substance against various microorganisms is shown in Table 2. [Table] [Table] Example 1 As seed medium, starch 2.0%, glucose 1.0
%, wheat germ 0.6%, polypeptone 0.5%, yeast extract 0.3%, soybean flour 0.2%, and calcium carbonate 0.1%. In addition, as a production medium, glucose 3.0%, wheat germ 1.5%, soybean flour 0.5%, corn staple liquor 1.0%, calcium carbonate 0.1%,
A medium containing 0.001% cobalt chloride was used. In addition,
The pH of all samples before sterilization was adjusted to PH7.0. A 100 ml Erlenmeyer flask containing 20 ml of the seed medium was sterilized at 120°C for 30 minutes, and Streptomyces sp. SF2446 (FERM P-8980) was added to the flask.
Platinum loops 1-2 of the slant culture were inoculated and cultured with shaking at 28°C for 3 days to obtain a type 1 culture. Then seed medium
A 500ml Erlenmeyer flask containing 80ml was heated at 120℃ for 30 minutes.
Sterilize for minutes, inoculate with 4 ml of the above-mentioned type 1 culture, and then at 28°C.
The cells were cultured with shaking for 2 days, and this was used as a second type culture. Furthermore, a 5 L Erlenmeyer flask into which 1 L of the seed medium was dispensed was sterilized at 120°C for 30 minutes, and 50 ml of the second type culture was inoculated and cultured with shaking at 28°C for one day to form the third type culture. Furthermore, 25L of seed medium, which had been sterilized in advance at 120℃ for 30 minutes, was dispensed into a 50L jar fermenter.
1 L of the 3rd type culture was inoculated and cultured with aeration at 28°C for 1 day, which was used as the 4th type culture. A 300 L jar fermenter containing 200 L of production medium previously sterilized at 120°C for 30 minutes was added to the
Inoculate 25L of seed culture and aerate at 28℃ for 5 days (20L/
minutes), stirring (initial 100 rpm, 130 rpm after 48 hours)
Cultured. After the culture was completed, diatomaceous earth was added as a filter aid and filtered. 158 L of 70% acetone water was added to the solid content containing bacterial cells obtained after filtration, stirred for 1 hour, and filtered again to obtain 158 L of bacterial cell extract containing active ingredients. Furthermore, the bacterial cell extract was concentrated under reduced pressure to remove acetone, the pH of 54 L of the aqueous layer was adjusted to 7, 54 L of ethyl acetate was added, and the mixture was stirred for 1 hour to extract the active ingredients. This operation was repeated twice, and anhydrous sodium sulfate was added to the obtained ethyl acetate extract to dry it, followed by concentration under reduced pressure to about 2 L. The concentrated solution was allowed to stand at 5° C. for one week, and then the precipitated crystals were filtered off, washed with cold methanol and then hexane, and dried to obtain 8.59 g of SF2446 substance. The filtrate and washings were combined and concentrated under reduced pressure to obtain a reddish-brown oily substance. This oily substance was placed on the top of a 2.4 L silica gel column (Wako Gel C-300, manufactured by Wako Pure Chemical Industries, Ltd.) pre-packed with chloroform, and after washing with 5 L of chloroform, it was developed with chloroform-methanol (10:1) to image the active image. The fractions were collected and concentrated under reduced pressure to obtain an oil. This operation was repeated twice, and the resulting oily substance was placed on the top of a similar 2.4 L silica gel column, washed with 1 L of chloroform, and then chloroform-
When developed with methanol (50:1) and a 200ml fraction cut, the fraction becomes 3 to 6 (Fr.).
The active area mainly containing the SF2446B1 substance is in fractions 7 to 14 (Fr.), and the active area mainly containing SF2446 substances and SF2446A3 substances is in fractions 15 to 18 (Fr.).
), the active areas mainly containing SF2446B2 substances are fractions 19 to 28 (Fr.) and fractions 29 to 40.
An active area containing mainly SF2446A2 substance was obtained in (Fr.). Fr. was concentrated to dryness under reduced pressure to obtain 650 mg of an oily substance. This oily substance was placed on top of a 120 ml silica gel column previously packed with hexane-acetone (2:1) and developed with the same solvent system to obtain a crude substance containing mainly SF2446B1 substance. This crude material was further purified by preparative silica gel TLC (developing system: hexane-acetone 1:1) to obtain 80.5 mg of SF2446B1 substance. Fr. was concentrated to dryness under reduced pressure to obtain 10.51 g of crude material. When this crude material was recrystallized using a chloroform-methanol (1:1) mixture, 1.82g of
SF2446 substance was obtained. The filtrate was concentrated under reduced pressure, and the resulting crude material was diluted with chloroform-methanol (1:
Sephadex LH-20 using 1) as a developing solvent
(750 ml, manufactured by Pharmacia) was subjected to column chromatography, and the active fraction was concentrated to dryness under reduced pressure.
If you repeat this operation two more times, you will receive 570mg of SF2446.
A crude material containing 303 mg of primarily SF2446A3 material was obtained. This crude material was transferred to a silica gel column (30 g, developing system: chloroform-methanol 30:
1) The product was then purified using a preparative silica gel column TLC (developing system: chloroform-methanol 15:1) to obtain 23.7 mg of SF2446A3 substance. Fr.
was concentrated to dryness under reduced pressure to obtain 772 mg of crude material. This crude material was prepared using silica gel (80 g) using chloroform-methanol (30:1) as the developing solvent.
Column chromatography was performed, and the obtained active fraction was concentrated to dryness under reduced pressure to obtain 123 mg of crude material. Furthermore, this crude material is transferred to preparative silica gel.
Purification by TLC (developing system: toluene-ethyl acetate 1:2, then chloroform-methanol 15:1) yielded 78.8 mg of SF2446B2 material. Fr.
was concentrated to dryness under reduced pressure to obtain 5.07 g of SF2446A2 substance. Similarly, when Fr. is concentrated to dryness under reduced pressure,
5.72g of crude material was obtained. This crude material was subjected to column chromatography on silica gel (300 g, developing system: chloroform-methanol 50:1), then column chromatography on silica gel (300 g, developing system: hexane-acetone 2:1), and further column chromatography on Cephadex LH-20 (developing system: hexane-acetone 2:1). System: chloroform-methanol 1:1) column chromatography was performed, and 1.13 g of SF2446A2 substance was obtained. Example 2 Concentrated hydrochloric acid (0.2 ml) was added to a methanol solution (2.2 ml) of SF2446B1 substance (15.2 mg), and the mixture was heated at 40°C for 1 hour.
I left it for a while. Then, the solvent was distilled off under reduced pressure,
When the residue was purified by preparative silica gel TLC (developing system: chloroform-methanol 15:1), 5.4 mg
SF2446B3 substance was obtained.

【図面の簡単な説明】[Brief explanation of the drawing]

第1図はSF2446A2物質(20μg/ml)の紫外部
及び可視部吸収スペクトルを示し、実線(―)は
メタノール溶液中、破線(……)は0.1規定塩酸
−メタノール溶液中、一点鎖線(―‐―)は0.1
規定水酸化ナトリウム−メタノール溶液中を示
す。第2図はSF2446A3物質(20μg/ml)の紫外
部及び可視部吸収スペクトルを示し、実線(―)
はメタノール溶液中、破線(……)は0.1規定塩
酸−メタノール溶液中、一点鎖線(―‐―)は
0.1規定水酸化ナトリウム−メタノール溶液中を
示す。第3図はSF2446B1物質(20μg/ml)の紫
外部及び可視部吸収スペクトルを示し、実線
(―)はメタノール溶液中、破線(……)は0.1規
定塩酸−メタノール溶液中、一点鎖線(―‐―)
は0.1規定水酸化ナトリウム−メタノール溶液中
を示す。第4図はSF2446B2物質(20μg/ml)の
紫外部及び可視部吸収スペクトルを示し、実線
(―)はメタノール溶液中、破線(……)は0.1規
定塩酸−メタノール溶液中、一点鎖線(―‐―)
は0.1規定水酸化ナトリウム−メタノール溶液中
を示す。第5図はSF2446B3物質(20μg/ml)の
紫外部及び可視部吸収スペクトルを示し、実線
(―)はメタノール溶液中、破線(……)は0.1規
定塩酸−メタノール溶液中、一点鎖線(―‐―)
は0.1規定水酸化ナトリウム−メタノール溶液中
を示す。第6図はSF2446A2物質の臭化カリウム
錠での赤外部吸収スペクトルを示す。第7図は
SF2446A3物質の臭化カリウム錠での赤外部吸収
スペクトルを示す。第8図はSF2446B1物質の臭
化カリウム錠での赤外部吸収スペクトルを示す。
第9図はSF2446B2物質の臭化カリウム錠での赤
外部吸収スペクトルを示す。第10図は
SF2446B3物質の臭化カリウム錠での赤外部吸収
スペクトルを示す。第11図はSF2446A2の重ク
ロロホルム溶液中、TMSを基準物質として測定
した400MHz1H NMRスペクトルを示す。第1
2図はSF2446A3の重クロロホルム溶液中、
TMSを基準物質として測定した400MHz1
NMRスペクトルを示す。第13図はSF2446B1
の重クロロホルム溶液中、TMSを基準物質とし
て測定した400MHz1H NMRスペクトルを示
す。第14図はSF2446B2の重クロロホルム溶液
中、TMSを基準物質として測定した400MHz1
NMRスペクトルを示す。第15図は
SF2446B3の重クロロホルム溶液中、TMSを基準
物質として測定した400MHz1H NMRスペクト
ルを示す。第16図はSF2446A2の重クロロホル
ム溶液中、TMSを基準物質として測定した100M
Hz13H NMRスペクトルを示す。第17図は
SF2446A3の重クロロホルム溶液中、TMSを基
準物質として測定した100MHz13H NMRスペク
トルを示す。第18図はSF2446B1の重クロロホ
ルム溶液中、TMSを基準物質として測定した
100MHz13H NMRスペクトルを示す。第19図
はSF2446B2の重クロロホルム溶液中、TMSを基
準物質として測定した100MHz13H NMRスペク
トルを示す第20図はSF2446B3の重クロロホル
ム溶液中、TMSを基準物質として測定した100M
Hz13H NMRスペクトルを示す。
Figure 1 shows the ultraviolet and visible absorption spectra of SF2446A2 substance (20μg/ml), where the solid line (-) is in methanol solution, the broken line (...) is in 0.1N hydrochloric acid-methanol solution, and the dashed line (-- --) is 0.1
Shown in normal sodium hydroxide-methanol solution. Figure 2 shows the ultraviolet and visible absorption spectra of SF2446A3 substance (20μg/ml), with solid line (-)
is in methanol solution, the dashed line (...) is in 0.1N hydrochloric acid-methanol solution, and the dashed line (---) is in methanol solution.
Shown in 0.1N sodium hydroxide-methanol solution. Figure 3 shows the ultraviolet and visible absorption spectra of SF2446B1 substance (20μg/ml), where the solid line (-) is in methanol solution, the broken line (...) is in 0.1N hydrochloric acid-methanol solution, and the dashed line (-- --)
indicates in 0.1N sodium hydroxide-methanol solution. Figure 4 shows the ultraviolet and visible absorption spectra of SF2446B2 substance (20μg/ml), where the solid line (-) is in methanol solution, the broken line (...) is in 0.1N hydrochloric acid-methanol solution, and the dashed line (-- --)
indicates in 0.1N sodium hydroxide-methanol solution. Figure 5 shows the ultraviolet and visible absorption spectra of SF2446B3 substance (20μg/ml), where the solid line (-) is in methanol solution, the broken line (...) is in 0.1N hydrochloric acid-methanol solution, and the dashed line (-- --)
indicates in 0.1N sodium hydroxide-methanol solution. Figure 6 shows the infrared absorption spectrum of SF2446A2 substance in potassium bromide tablets. Figure 7 is
The infrared absorption spectrum of SF2446A3 substance in potassium bromide tablets is shown. Figure 8 shows the infrared absorption spectrum of SF2446B1 substance in potassium bromide tablets.
Figure 9 shows the infrared absorption spectrum of SF2446B2 substance in potassium bromide tablets. Figure 10 is
The infrared absorption spectrum of SF2446B3 substance in potassium bromide tablets is shown. FIG. 11 shows a 400MHz 1 H NMR spectrum measured in a deuterated chloroform solution of SF2446A2 using TMS as a reference substance. 1st
Figure 2 shows SF2446A3 in deuterated chloroform solution.
400MHz 1H measured using TMS as a reference material
The NMR spectrum is shown. Figure 13 is SF2446B1
This shows a 400MHz 1 H NMR spectrum measured in a deuterated chloroform solution using TMS as a reference substance. Figure 14 shows 400MHz 1 H measured in a deuterated chloroform solution of SF2446B2 using TMS as a reference material.
The NMR spectrum is shown. Figure 15 is
The figure shows a 400MHz 1 H NMR spectrum measured in a deuterated chloroform solution of SF2446B3 using TMS as a reference substance. Figure 16 shows 100M of SF2446A2 measured in deuterated chloroform solution using TMS as a reference substance.
The Hz 13 H NMR spectrum is shown. Figure 17 is
The figure shows a 100MHz 13 H NMR spectrum measured in a deuterated chloroform solution of SF2446A3 using TMS as a reference substance. Figure 18 shows measurements of SF2446B1 in deuterated chloroform solution using TMS as a reference substance.
A 100MHz 13H NMR spectrum is shown. Figure 19 shows a 100MHz 13 H NMR spectrum measured in a deuterated chloroform solution of SF2446B2 using TMS as a reference substance. Figure 20 shows a 100MHz 13 H NMR spectrum measured in a deuterated chloroform solution of SF2446B3 using TMS as a reference substance.
The Hz 13 H NMR spectrum is shown.

Claims (1)

【特許請求の範囲】 1 下記の化学構造式を有する新規抗生物質
SF2446A2,A3,B1,B2,B3物質およびそれら
の塩;
[Claims] 1. A novel antibiotic having the following chemical structural formula:
SF2446A2, A3, B1, B2, B3 substances and their salts;
JP25386087A 1987-10-09 1987-10-09 Novel antibiotic sf2446a2 substance, sf2446a3 substance, sf2446 b1 substance, sf2446b2 substance and sf2446b3 substance Granted JPH0196189A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP25386087A JPH0196189A (en) 1987-10-09 1987-10-09 Novel antibiotic sf2446a2 substance, sf2446a3 substance, sf2446 b1 substance, sf2446b2 substance and sf2446b3 substance

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP25386087A JPH0196189A (en) 1987-10-09 1987-10-09 Novel antibiotic sf2446a2 substance, sf2446a3 substance, sf2446 b1 substance, sf2446b2 substance and sf2446b3 substance

Publications (2)

Publication Number Publication Date
JPH0196189A JPH0196189A (en) 1989-04-14
JPH05380B2 true JPH05380B2 (en) 1993-01-05

Family

ID=17257137

Family Applications (1)

Application Number Title Priority Date Filing Date
JP25386087A Granted JPH0196189A (en) 1987-10-09 1987-10-09 Novel antibiotic sf2446a2 substance, sf2446a3 substance, sf2446 b1 substance, sf2446b2 substance and sf2446b3 substance

Country Status (1)

Country Link
JP (1) JPH0196189A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754054B2 (en) 2010-07-09 2014-06-17 Albany Molecular Research, Inc. Antibacterial compounds, methods of making them, and uses thereof
AU2016362540B2 (en) 2015-12-02 2022-04-28 Fondazione Istituto Insubrico Di Ricerca Per La Vita Antibiotic FIIRV 104/18 complex and the isolated individual factors thereof

Also Published As

Publication number Publication date
JPH0196189A (en) 1989-04-14

Similar Documents

Publication Publication Date Title
NO150785B (en) PROCEDURE FOR THE PREPARATION OF DRY STARCH FOODS
JPH04352783A (en) 12-membered ring macrolide compound
JPS6254433B2 (en)
JPH05380B2 (en)
JPS6220984B2 (en)
JP2873894B2 (en) Cyclic depsipeptide and method for producing the same
JPS62263196A (en) 14-hydroxyerythromycin derivative and production thereof
JPH0625095B2 (en) Antibiotic SF-2415 substance and its production method
JPH0353891A (en) New antibiotic substance sf2197c and production thereof
JPH0374677B2 (en)
JPS63154695A (en) Novel antibiotic substance sf2446 and production thereof
JPH06234784A (en) New antibiotic sf 2768 substance and its production
JP3380595B2 (en) Novel antibiotics SF2741A and SF2741B and their production
JP3192723B2 (en) Novel macrolide antibiotics SF2748B, SF2748C1, SF2748D and SF2748E and their production
JP2594085B2 (en) SF2575, a new antitumor antibiotic, and method for producing the same
JPH0639480B2 (en) New macrolide antibiotic M119
KR840000934B1 (en) Process for preparing antibiotic sf-2080 a and sf-2080 b
US3557151A (en) The compound(+)-5'-hydroxygriseofulvin
JPS59170092A (en) Novel antibiotic, ss8201d and its preparation
US3616238A (en) Method of preparing (+)-5'-hydroxygriseofulvin
JPH0417199B2 (en)
JPH0531552B2 (en)
JPH0422917B2 (en)
JPS63107993A (en) Antibiotic substance tm-611
JPH06316595A (en) Cyclic peptide compound